senolytic zombie cells

Senolytics are drugs and other therapeutics that kill senescent zombie cells and activate autophagy, the natural mechanism whereby we clear senescent cells from our bodies. Autophagy (literally self-digesting) is an essential mechanism that is taking place every second of our lives. But as we age, we accumulate greater populations of senescent cells, and the natural process of senolysis is inhibited. Our modern lifestyles of overabundance of nutrients inhibits the natural activation of autophagy and leads to greater and greater numbers of senescence cells. Adiposity, and in particular visceral adiposity, are the hallmarks of an inhibited system of autophagy.

The resultant life-long accumulation of senescent zombie cells causes the over expression of what is known as the senescence associated secretory phenotype, or SASP, which means that these senescent cells are actively secreting toxic compounds that not only poison our cellular well, these SASP cells actively recruit neighboring cells to become senescent, thereby increasing the burden of senescent cells in our bodies. This further drives the progression of age-related diseases. Therefore, the process of Zombie cell autophagy and the therapeutic use of senolytics to accelerate senolysis is the subject of a growing segment of scientific research dedicated to the enhancement of our natural longevity pathways.


Dr. Noel Peterson, ND, DAAPM, is the Medical Director of Oregon Regenerative Medicine, and has practiced naturopathic medicine in Lake Oswego, OR, since 1978. He specializes in natural and regenerative cellular medicine, including Prolotherapy, PRP (Platelet Rich Plasma), and Autologous Stem Cell therapy. Peterson has taught prolotherapy nationally and internationally. In 2019, the Oregon Director Association of Naturopathic Physicians (OANP) and National University of Natural Medicine (NUNM) selected Dr. Peterson to be honored with naturopathic medicine’s prestigious Living Legend Award.

Sources

Senotherapeutics: emerging strategy for healthy aging and age-related disease. Kim EC, Kim JR. BMB Rep. 2019 Jan;52(1):47-55. doi: 10.5483/BMBRep.2019.52.1.293. PMID: 30526770; PMCID: PMC6386227

First-in-human trial of senolytic drugs encouraging, University of Texas Health Science Center at San Antonio, January 2019